The Experts below are selected from a list of 6174 Experts worldwide ranked by ideXlab platform
Joseph G Vehige - One of the best experts on this subject based on the ideXlab platform.
-
safety and efficacy of a preservative free Artificial Tear containing carboxymethylcellulose and hyaluronic acid for dry eye disease a randomized controlled multicenter 3 month study
Clinical Ophthalmology, 2020Co-Authors: Pasquale Aragona, J M Benitezdelcastillo, Cindy Carlislewilcox, Jacqueline Tan, Haixia Liu, Mt Coroneo, Subhanjan Mukherji, Evelien Vandewalle, Algis J Vingrys, Joseph G VehigeAbstract:Purpose To compare the efficacy and safety of an Artificial Tear combining the polymers carboxymethylcellulose (CMC) and hyaluronic acid (HA), to a formulation of CMC alone in subjects with dry eye. Methods A preservative-free Artificial Tear (CMC-HA) was compared with an existing Artificial Tear (CMC). Subjects with mild-to-severe signs and symptoms of dry eye were enrolled in this double-masked, randomized, multicenter trial, and dosed at least twice daily for 90 days, with follow-up visits at Days 7, 30, 60, and 90. Ocular Surface Disease Index (OSDI) was the primary outcome measure. Secondary outcome measures were Tear break-up time (TBUT), ocular surface staining, Schirmer test with anesthesia, and visual analog scale (VAS) scores of dry eye symptom severity and formulation acceptability. Safety measures included adverse events, biomicroscopy, and visual acuity. Results A total of 460 subjects were enrolled across 45 sites (38 in Europe; 7 in Australia), of whom 454 were randomized to receive treatment. The per-protocol (PP) population consisted of 394 subjects, 364 (92.4%) of whom completed the study. In the PP population, the mean ± SD change from baseline in OSDI score at the primary timepoint, Day 90, was -16.9±17.5 for CMC-HA and -16.0±16.1 for CMC. CMC-HA was non-inferior to CMC based upon a confidence interval method. Both treatments significantly improved (P<0.001) OSDI, symptom VAS scores, TBUT, and ocular surface staining from baseline at all follow-up visits, with minimal differences between groups. Greater reduction of overall ocular pain/discomfort was reported in subjects using CMC-HA versus CMC (P=0.048). Approximately 10% of subjects in each group reported treatment-related adverse events of generally mild to moderate severity. Conclusion The new CMC-HA formulation was effective and well tolerated, and demonstrates a greater potential for symptom relief compared with CMC. These data support implementation of this formula for the management of dry eye patients.
-
an Artificial Tear containing flaxseed oil for treating dry eye disease a randomized controlled trial
Ocular Surface, 2020Co-Authors: Laura E Downie, Gregg J. Berdy, Peter A Simmons, Cindy Carlislewilcox, Milton M Hom, Sherif Elharazi, Anthony Verachtert, Jacqueline Tan, Haixia Liu, Joseph G VehigeAbstract:Abstract Purpose To evaluate the efficacy and safety of a nano-emulsion Artificial Tear (OM3) containing carboxymethylcellulose (CMC) and glycerin, flaxseed oil and castor oil, and three osmoprotectants (levocarnitine, erythritol, and trehalose) compared with an Artificial Tear (Refresh Optive Advanced [ROA]) containing the same ingredients with the exception of trehalose and flaxseed oil. Methods In this multicenter, double-masked, randomized, two-arm, parallel-group, 6-visit study (screening, baseline, and days 7, 30, 60, and 90), subjects with dry eye disease underwent an open-label, 7-day run-in with CMC 0.5% (Refresh Plus), before 1:1 randomization to OM3 or ROA for 90 days (both instilled ≥2 daily). Ocular Surface Disease Index (OSDI; primary endpoint change from baseline at day 90), Tear film breakup time (TBUT), and ocular staining (combined/corneal/conjunctival) were assessed; change from baseline in these parameters was calculated at each timepoint. Treatment-related adverse events (AEs) were assessed at each visit. Results Overall, 242 subjects were randomized (OM3, n = 120; ROA, n = 122). At day 90, significant improvements in OSDI, ocular staining and TBUT were evident in both treatment groups. Significant (P Conclusion These findings support the application of OM3, a novel preservative-free, nano-emulsion Tear formulation with trehalose and flaxseed oil, for the treatment of dry eye disease.
-
evaluation of an enhanced viscosity Artificial Tear for moderate to severe dry eye disease a multicenter double masked randomized 30 day study
Contact Lens and Anterior Eye, 2019Co-Authors: Christopher W Lievens, Gregg J. Berdy, Peter A Simmons, Joseph G Vehige, David Douglass, Stephen Montaquila, Hugh Lin, Cindy Carlislewilcox, Sameena HaqueAbstract:Abstract Purpose In a randomized, controlled clinical trial, two lubricant Artificial Tear formulations with enhanced viscosity were compared: an investigational product at the time, containing carboxymethylcellulose 1.0% and glycerin 0.9% (CMC-GLY) with osmoprotectants, and a standard formula containing carboxymethylcellulose 1.0% alone (CMC). Methods This double-masked study recruited patients with moderate to severe dry eye at 10 US centers. After a 7-day run-in with CMC 0.5% (Refresh Tears) patients were randomized to use either CMC-GLY or CMC as needed, but at least 2 times daily for 30 days. Patients were stratified by Ocular Surface Disease Index© (OSDI) score into moderate (23–32) and severe (> 32–65) subgroups. Assessments included OSDI (primary efficacy variable), corneal and conjunctival staining, Tear break-up time (TBUT), symptom surveys, and safety variables. Study visits were days 1 (baseline/randomization), 7, and 30. Results A total of 188 patients (94 CMC-GLY, 94 CMC) were enrolled. The severe subgroup had 67 CMC-GLY and 65 CMC patients. OSDI scores progressively improved and were similar at day 30 between treatment groups. At day 7, only the CMC-GLY group demonstrated significant improvements from baseline in OSDI score (all patients p Conclusions Overall, the CMC-GLY Artificial Tear formulation was as effective as the CMC formulation. CMC-GLY demonstrated improvements at an earlier stage (day 7). Both Artificial Tear formulations were safe and well tolerated, with no treatment-related serious adverse events. These results support the use of the CMC-GLY Artificial Tear formulation as an effective treatment to reduce the symptoms and signs of dry eye disease.
-
investigating the potential benefits of a new Artificial Tear formulation combining two polymers
Clinical Ophthalmology, 2017Co-Authors: Peter A Simmons, Joseph G VehigeAbstract:PURPOSE Artificial Tear formulations typically contain a water-soluble polymer to enhance residence time, moisture retention, and binding to the mucin coat of the ocular surface, which facilitate corneal healing. This study investigated the potential advantages of combining carboxymethylcellulose (CMC) and hyaluronic acid (HA) polymers in a single formulation. MATERIALS AND METHODS Individual CMC and HA solutions were prepared and tested for bulk viscosity in comparison to a solution that combined CMC and HA. Rheometry determined the differences between solutions at increasing shear rates, simulating eye movement and blinking. RESULTS The bulk viscosity of the individual 0.5% CMC and 0.1% HA solutions was 2.5 and 5.7 cP, respectively. The viscosity of the combined solution (13.1 cP) was 60% higher than predicted by additive effects. Rheometry revealed shear rates between 10/second (open eye) and 10,000/second (blinking eye). At these rates, viscosity ranged from 2.7 to 3.5 cP for 0.5% CMC, 2.8 to 6.8 cP for 0.1% HA, and 5.2 to 15.3 cP for the 0.5% CMC-0.1% HA combination. Low-shear viscosity of the CMC-HA combination increased 48% over the sum of the individual solutions, but high-shear viscosity remained virtually unchanged. Data from CMC and HA solutions at higher concentrations were consistent with these results. CONCLUSION Combining CMC and HA polymers produced a synergistic increase in low-shear viscosity (which cannot be fully explained by simple molecular entanglement), while the high-shear viscoelasticity of the combined solution remained unaffected. These data suggest that CMC-HA combinations have properties that may be used to formulate Artificial Tears that optimize ocular retention (through higher low-shear viscosity), while minimizing blur and stickiness during blinking (through lower high-shear viscosity).
-
Evaluation of a Novel Artificial Tear in the Prevention and Treatment of Dry Eye in an Animal Model
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2015Co-Authors: Yujing She, Peter A Simmons, Joseph G Vehige, Haixia Liu, Bing Xiao, Wei ChenAbstract:Abstract Purpose: To evaluate effects of a novel multi-ingredient Artificial Tear formulation containing carboxymethylcellulose (CMC) and hyaluronic acid (HA) in a murine dry eye model. Methods: Dry eye was induced in mice (C57BL/6) using an intelligently controlled environmental system (ICES). CMC+HA (Optive Fusion™), CMC-only (Refresh Tears®), and HA-only (Hycosan®) Artificial Tears and control phosphate-buffered saline (PBS) were administered 4 times daily and compared with no treatment (n = 64 eyes per group). During regimen 1 (prevention regimen), mice were administered Artificial Tears or PBS for 14 days (starting day 0) while they were exposed to ICES, and assessed on days 0 and 14. During regimen 2 (treatment regimen), mice exposed to ICES for 14 days with no intervention were administered Artificial Tears or PBS for 14 days (starting day 14) while continuing exposure to ICES, and assessed on days 0, 14, and 28. Corneal fluorescein staining and conjunctival goblet cell density were measured. Resul...
Peter A Simmons - One of the best experts on this subject based on the ideXlab platform.
-
an Artificial Tear containing flaxseed oil for treating dry eye disease a randomized controlled trial
Ocular Surface, 2020Co-Authors: Laura E Downie, Gregg J. Berdy, Peter A Simmons, Cindy Carlislewilcox, Milton M Hom, Sherif Elharazi, Anthony Verachtert, Jacqueline Tan, Haixia Liu, Joseph G VehigeAbstract:Abstract Purpose To evaluate the efficacy and safety of a nano-emulsion Artificial Tear (OM3) containing carboxymethylcellulose (CMC) and glycerin, flaxseed oil and castor oil, and three osmoprotectants (levocarnitine, erythritol, and trehalose) compared with an Artificial Tear (Refresh Optive Advanced [ROA]) containing the same ingredients with the exception of trehalose and flaxseed oil. Methods In this multicenter, double-masked, randomized, two-arm, parallel-group, 6-visit study (screening, baseline, and days 7, 30, 60, and 90), subjects with dry eye disease underwent an open-label, 7-day run-in with CMC 0.5% (Refresh Plus), before 1:1 randomization to OM3 or ROA for 90 days (both instilled ≥2 daily). Ocular Surface Disease Index (OSDI; primary endpoint change from baseline at day 90), Tear film breakup time (TBUT), and ocular staining (combined/corneal/conjunctival) were assessed; change from baseline in these parameters was calculated at each timepoint. Treatment-related adverse events (AEs) were assessed at each visit. Results Overall, 242 subjects were randomized (OM3, n = 120; ROA, n = 122). At day 90, significant improvements in OSDI, ocular staining and TBUT were evident in both treatment groups. Significant (P Conclusion These findings support the application of OM3, a novel preservative-free, nano-emulsion Tear formulation with trehalose and flaxseed oil, for the treatment of dry eye disease.
-
evaluation of an enhanced viscosity Artificial Tear for moderate to severe dry eye disease a multicenter double masked randomized 30 day study
Contact Lens and Anterior Eye, 2019Co-Authors: Christopher W Lievens, Gregg J. Berdy, Peter A Simmons, Joseph G Vehige, David Douglass, Stephen Montaquila, Hugh Lin, Cindy Carlislewilcox, Sameena HaqueAbstract:Abstract Purpose In a randomized, controlled clinical trial, two lubricant Artificial Tear formulations with enhanced viscosity were compared: an investigational product at the time, containing carboxymethylcellulose 1.0% and glycerin 0.9% (CMC-GLY) with osmoprotectants, and a standard formula containing carboxymethylcellulose 1.0% alone (CMC). Methods This double-masked study recruited patients with moderate to severe dry eye at 10 US centers. After a 7-day run-in with CMC 0.5% (Refresh Tears) patients were randomized to use either CMC-GLY or CMC as needed, but at least 2 times daily for 30 days. Patients were stratified by Ocular Surface Disease Index© (OSDI) score into moderate (23–32) and severe (> 32–65) subgroups. Assessments included OSDI (primary efficacy variable), corneal and conjunctival staining, Tear break-up time (TBUT), symptom surveys, and safety variables. Study visits were days 1 (baseline/randomization), 7, and 30. Results A total of 188 patients (94 CMC-GLY, 94 CMC) were enrolled. The severe subgroup had 67 CMC-GLY and 65 CMC patients. OSDI scores progressively improved and were similar at day 30 between treatment groups. At day 7, only the CMC-GLY group demonstrated significant improvements from baseline in OSDI score (all patients p Conclusions Overall, the CMC-GLY Artificial Tear formulation was as effective as the CMC formulation. CMC-GLY demonstrated improvements at an earlier stage (day 7). Both Artificial Tear formulations were safe and well tolerated, with no treatment-related serious adverse events. These results support the use of the CMC-GLY Artificial Tear formulation as an effective treatment to reduce the symptoms and signs of dry eye disease.
-
investigating the potential benefits of a new Artificial Tear formulation combining two polymers
Clinical Ophthalmology, 2017Co-Authors: Peter A Simmons, Joseph G VehigeAbstract:PURPOSE Artificial Tear formulations typically contain a water-soluble polymer to enhance residence time, moisture retention, and binding to the mucin coat of the ocular surface, which facilitate corneal healing. This study investigated the potential advantages of combining carboxymethylcellulose (CMC) and hyaluronic acid (HA) polymers in a single formulation. MATERIALS AND METHODS Individual CMC and HA solutions were prepared and tested for bulk viscosity in comparison to a solution that combined CMC and HA. Rheometry determined the differences between solutions at increasing shear rates, simulating eye movement and blinking. RESULTS The bulk viscosity of the individual 0.5% CMC and 0.1% HA solutions was 2.5 and 5.7 cP, respectively. The viscosity of the combined solution (13.1 cP) was 60% higher than predicted by additive effects. Rheometry revealed shear rates between 10/second (open eye) and 10,000/second (blinking eye). At these rates, viscosity ranged from 2.7 to 3.5 cP for 0.5% CMC, 2.8 to 6.8 cP for 0.1% HA, and 5.2 to 15.3 cP for the 0.5% CMC-0.1% HA combination. Low-shear viscosity of the CMC-HA combination increased 48% over the sum of the individual solutions, but high-shear viscosity remained virtually unchanged. Data from CMC and HA solutions at higher concentrations were consistent with these results. CONCLUSION Combining CMC and HA polymers produced a synergistic increase in low-shear viscosity (which cannot be fully explained by simple molecular entanglement), while the high-shear viscoelasticity of the combined solution remained unaffected. These data suggest that CMC-HA combinations have properties that may be used to formulate Artificial Tears that optimize ocular retention (through higher low-shear viscosity), while minimizing blur and stickiness during blinking (through lower high-shear viscosity).
-
Evaluation of a Novel Artificial Tear in the Prevention and Treatment of Dry Eye in an Animal Model
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2015Co-Authors: Yujing She, Peter A Simmons, Joseph G Vehige, Haixia Liu, Bing Xiao, Wei ChenAbstract:Abstract Purpose: To evaluate effects of a novel multi-ingredient Artificial Tear formulation containing carboxymethylcellulose (CMC) and hyaluronic acid (HA) in a murine dry eye model. Methods: Dry eye was induced in mice (C57BL/6) using an intelligently controlled environmental system (ICES). CMC+HA (Optive Fusion™), CMC-only (Refresh Tears®), and HA-only (Hycosan®) Artificial Tears and control phosphate-buffered saline (PBS) were administered 4 times daily and compared with no treatment (n = 64 eyes per group). During regimen 1 (prevention regimen), mice were administered Artificial Tears or PBS for 14 days (starting day 0) while they were exposed to ICES, and assessed on days 0 and 14. During regimen 2 (treatment regimen), mice exposed to ICES for 14 days with no intervention were administered Artificial Tears or PBS for 14 days (starting day 14) while continuing exposure to ICES, and assessed on days 0, 14, and 28. Corneal fluorescein staining and conjunctival goblet cell density were measured. Resul...
-
efficacy safety and acceptability of a lipid based Artificial Tear formulation a randomized controlled multicenter clinical trial
Clinical Therapeutics, 2015Co-Authors: Peter A Simmons, Cindy Carlislewilcox, Haixia Liu, Ru Chen, Joseph G VehigeAbstract:Abstract Purpose Dry eye disease is highly prevalent worldwide, causing discomfort and visual disturbances that can limit basic activities such as reading and driving. Although Artificial Tears represent first-line therapy, there is a paucity of published controlled clinical trials. The present study compared the efficacy, clinical safety, and acceptability of 2 multicomponent, lipid-based Tear formulations (ADV1 and ADV2) to those of an existing lipid-based Tear formulation (DET) in patients with signs and symptoms of dry eye disease. Methods This 3-month, multicenter, double-masked study was conducted in patients with dry eye symptoms, reduced Tear break-up time (TBUT), and ocular surface damage. Patients were randomized to receive 1 of 2 lipid-based Tear formulations containing carboxymethylcellulose, glycerin, polysorbate 80, and emulsified lipid (ADV1 or ADV2) or DET, and instilled 1 to 2 drops per eye at least twice daily. The primary end point was the mean change from baseline in Subjective Evaluation of Symptom of Dryness score at day 90 to determine noninferiority of the 2 ADV formulations versus DET. Secondary end points included Ocular Surface Disease Index (OSDI) score, TBUT, ocular surface staining, and tolerability. Findings Of 288 randomized patients, 256 completed the study. All 3 groups showed improvement in symptoms, and the 2 lipid-based formulations were noninferior to DET in reducing the severity of symptoms of dryness at 90 days. Of the 3 treatment groups, the ADV2 group had the greatest improvements in TBUT and OSDI. Significant improvements in mean tolerability scores for comfort, soothing, burning/stinging, and discomfort were observed in the ADV2 group versus the DET group at 90 days. Treatment-related adverse events were reported in 13 patients (13.4%) receiving ADV1, 8 (8.4%) receiving ADV2, and 21 (21.9%) receiving DET. Four patients (4.1%) in the ADV1 group and 2 (2.1%) in the ADV2 group discontinued owing to an adverse event compared with 14 (14.6%) receiving DET. Implications In these patients with dry eye symptoms, ADV2 was an effective and relatively well-tolerated Artificial Tear for first-line therapy and should be considered as a treatment option for dry eye, especially in those patients who would benefit from a lipid-based formulation in addition to lubrication. https://clinicaltrials.gov/ct2/show/NCT01010282.
John L. Ubels - One of the best experts on this subject based on the ideXlab platform.
-
Pre-clinical investigation of the efficacy of an Artificial Tear solution containing hydroxypropyl-guar as a gelling agent
Current eye research, 2004Co-Authors: John L. Ubels, Daniel P. Clousing, Timothy A Van Haitsma, Bor-shyue Hong, Peggy Stauffer, Bahram Asgharian, David L. MeadowsAbstract:Purpose. Pre-clinical studies of a new Artificial Tear product (SystaneTM Lubricating Eye Drops Alcon Laboratories, Inc., Fort Worth, TX) containing the novel gelling agent hydroxypropyl-guar (HP-guar) and two demulcents, polyethylene glycol 400 (PEG) and propylene glycol (PG) were conducted to determine the ability of the product to protect ocular surface epithelial cells from desiccation in vivo and in vitro, and to promote recovery of the damaged corneal epithelial barrier in vivo. Other leading Artificial Tear products were also evaluated as comparators to determine the relative effectiveness of different polymer systems. Methods. Damage due to desiccation was assessed by measuring corneal uptake of methylene blue compared to untreated corneas. Corneas of anesthetized rabbits were treated with the new Artificial Tear product and subjected to desiccation by holding the eyelids open for 2 hours with a speculum. Control eyes were subjected to desiccation without application of a Tear formulation. To meas...
-
Artificial Tear SOLUTIONS AND PROTECTION OF THE CORNEAL EPITHELIUM FROM DESICCATION
Journal of Toxicology: Cutaneous and Ocular Toxicology, 2002Co-Authors: John L. Ubels, Mark D. Aupperlee, David L. MeadowsAbstract:Desiccation of the ocular surface in dry environments is one of the factors contributing to discomfort in dry eye patients. An in vivo desiccation model was used to test efficacy of Artificial Tear products for prevention of ocular surface damage during extended desiccating exposure. One drop of an Artificial Tear or a lens rewetting solution was placed on the eye of an anesthetized rabbit and the eye was held open with a speculum for 2 hr. Desiccated eyes were held open for 2 hr without application of a Tear solution. Eyes were stained with 1% methylene blue in BSS. Naive control eyes were stained with methylene blue without prior desiccation. The percentage of corneal area stained was scored and a 8-mm button of central cornea was extracted in acetone:saturated sodium sulfate (7:3). Absorbance of extracts was measured at 660 nm. Extract analysis showed that four of the five Tear products tested offered complete protection from desiccation (not different from naive control), while one solution, which was...
-
effects of preservative free Artificial Tear solutions on corneal epithelial structure and function
Archives of Ophthalmology, 1995Co-Authors: John L. Ubels, Mitchell D Mccartney, William Lantz, Jonnell Beaird, Ashim Dayalan, Henry F EdelhauserAbstract:Objectives: To test the efficacy of a bicarbonate-containing Artificial physiologic Tear solution (solution PT) in providing an environment in which the damaged corneal epithelium can recover its normal barrier function and to compare this solution with other available Artificial Tears. Also, to investigate the effects on the corneal mucin layer and epithelial ultrastructure. Methods: The corneal epithelial permeability of anesthetized rabbits was increased by exposure to 0.1% benzalkonium chloride. The corneas were then exposed to solution PT, with or without bicarbonate, or one of four commercially available Artificial Tear solutions for 1.5 hours, followed by a 5-minute exposure to 5(6)-carboxyfluorescein. Frozen sections of the corneas were examined by fluorescence microscopy. The fluorescence intensity (FI) of the epithelium was measured by image analysis. Undamaged corneas exposed to Tear solutions were examined by transmission electron microscopy after fixation of the mucin layer with cetylpyridinium chloride. Results: The FI of corneas damaged by benzalkonium chloride was increased threefold above those of undamaged controls. Damaged corneas treated with either of two commercial isotonic Tear solutions partially recovered their barrier function, but the FI did not reach control levels. Corneas treated with hypotonic solutions containing ethylenediaminetetraacetic acid (EDTA) did not recover. In contrast, the FI of corneas treated with solution PT returned to control levels. This effect was lost in the absence of bicarbonate. Solution PT and the two isotonic solutions maintained normal corneal ultrastructure and mucin layer. Lack of bicarbonate in solution PT resulted in focal damage to superficial epithelial cells, whereas the EDTA-containing solutions destroyed the first two cell layers and reduced the mucin thickness. Conclusions: Bicarbonate-containing solution PT is superior to the other Tear solutions tested in promoting recovery of the damaged corneal epithelial barrier and maintaining normal ultrastructure. The presence of bicarbonate appears to be essential to this process.
-
evaluation of effects of a physiologic Artificial Tear on the corneal epithelial barrier electrical resistance and carboxyfluorescein permeability
Advances in Experimental Medicine and Biology, 1994Co-Authors: John L. Ubels, Dolores Lopez Bernal, Keven K Williams, Henry F EdelhauserAbstract:Artificial Tear solutions are widely used for relief of ocular surface irritation by patients with dry eye syndromes and by persons with ocular discomfort due to climatic conditions, air pollutants and various other causes. Although about 200,000 persons in the United States are classified as having a severe dry eye, nearly 5 million people report using dry eye protectants, resulting in the purchase of over 10 million units of ethical over-the-counter Artificial Tears worth nearly $80 million dollars per year1. This has resulted in a highly competitive market for these products with at least 25 different solutions currently on the market in the United States2 and new ones appearing frequently.
-
Artificial Tear Composition and Promotion of Recovery of the Damaged Corneal Epithelium
Cornea, 1993Co-Authors: Dolores Lopez Bernal, John L. UbelsAbstract:In severe dry eye syndromes the corneal epithelium is compromised with development of punctate erosions and increased permeability. In the present study the ability of Artificial Tear solutions to promote recovery of the corneal epithelial barrier was determined by measurement of corneal uptake of 5
Penny A Asbell - One of the best experts on this subject based on the ideXlab platform.
-
increasing importance of dry eye syndrome and the ideal Artificial Tear consensus views from a roundtable discussion
Current Medical Research and Opinion, 2006Co-Authors: Penny A AsbellAbstract:BACKGROUND: Dry eye syndrome is a highly prevalent, yet largely under diagnosed, condition that can substantially affect quality of life. Left untreated, dry eye is associated with chronic eye pain and increased risk of ocular surface disease. Current demographic changes and lifestyle factors indicate that the dry eye syndrome patient population will increase significantly, ensuring that general practitioners and ophthalmic clinicians alike will experience more patients presenting with dry eye symptoms. Greater public and practitioner awareness of emerging research, technologies, and therapies is crucial to ensuring appropriate interventions to meet specific patient needs and result in clinically favorable outcomes. ROUNDTABLE ASSEMBLY: In August 2005, a team of ocular surface experts convened for a 1-day roundtable session to discuss the latest information on diagnosing and treating dry eye syndrome and real-world issues in Artificial Tear therapy, including preservative use. ROUNDTABLE DISCUSSION: The discussion centered on the mild to moderate dry eye patient and critical features of the ideal Artificial Tear, which are preservative-free formulation, protection from microbial contamination, cost-effective, non-blurring, and easy to use. Products that match this profile have the advantage of being able to benefit the myriad of patients who comprise the dry eye syndrome population. Ocular surface health should always remain a top priority. Preferred Practice Pattern Dry Eye Syndrome Medical Treatment guidelines should be modified to recommend the use of preservative-free formula Artificial Tear products for all levels of dry eye conditions in consideration of the medical benefit they offer to dry eye syndrome sufferers. CONCLUSION: The growing prevalence of dry eye syndrome demands increased attention. Further research, enhanced diagnostic tests, increased use of preservative-free Artificial Tear formulations as first-line therapy, greater patient-practitioner interaction, and patient education are warranted.
-
increasing importance of dry eye syndrome and the ideal Artificial Tear consensus views from a roundtable discussion
Current Medical Research and Opinion, 2006Co-Authors: Penny A AsbellAbstract:ABSTRACTBackground: Dry eye syndrome is a highly prevalent, yet largely under diagnosed, condition that can substantially affect quality of life. Left untreated, dry eye is associated with chronic eye pain and increased risk of ocular surface disease. Current demographic changes and lifestyle factors indicate that the dry eye syndrome patient population will increase significantly, ensuring that general practitioners and ophthalmic clinicians alike will experience more patients presenting with dry eye symptoms. Greater public and practitioner awareness of emerging research, technologies, and therapies is crucial to ensuring appropriate interventions to meet specific patient needs and result in clinically favorable outcomes.Roundtable assembly: In August 2005, a team of ocular surface experts convened for a 1‐day roundtable session to discuss the latest information on diagnosing and treating dry eye syndrome and real-world issues in Artificial Tear therapy, including preservative use.Roundtable discussion:...
Scott R. Rossi - One of the best experts on this subject based on the ideXlab platform.
-
a unique therapeutic Artificial Tear formulation
Advances in Experimental Medicine and Biology, 1994Co-Authors: Jeffrey P. Gilbard, Scott R. RossiAbstract:The Tear film has a unique electrolyte balance distinct from aqueous humor and serum.1. We postulated that this electrolyte balance was critical for the maintenance of ocular surface health.
